OTS - The Top of the Tops of international Biotech and Pharma Pays a Visit to Berlin
2017. October 24. 11:15
Berlin, 24 October, 2017 (APA/OTS) - From November 6 to 8, 2017,
CityCube Berlin will host a virtual who's who on the international
biotech scene. Investors, startups and leading decision makers from
the biotech, pharmaceutical and finance sectors will gather for
three days of intensive exchange at the international BIO-Europe.
High-ranking guests will participate in workshops, panels and those
popular pre-scheduled one-on-one meetings that make the conference
so unique. The aim of the get-together is to foster innovative and
value-generating ideas by uniting joint interests and expertise.
In 2017, Berlin will host the BIO-Europe with support from
Berlin Partner and the regional Cluster for Healthcare Industry and
Life Sciences HealthCapital which will showcase its activities to
international guests and also work to bring regional actors
together with decision makers from across Germany and abroad. The
cluster's agenda will focus on support for internationalization,
regional excellence and future-oriented innovation. Carolin
Clement, head of Unit Biotech/Pharma at Berlin Partner for Business
and Technology, which manages the HealthCapital cluster, noted:
"Among our tasks are highlighting the life sciences region on an
international level and facilitating the creation of new companies
and cooperative activities. Tradeshows and congresses like
BIO-Europe offer the ideal platform to do just that. We provide
custom-made location tours and information to all guests, and our
in-depth knowledge of the region's major business and science
stakeholders, infrastructure and commercial sites makes it possible
for us to generate the right contacts for each respective need."
The region's roughly 5,000 employees at over 230 companies make
a significant contribution to the federal state's expanding
expertise and economic strength. Roughly 80?% carry out R&D in the
realm of biomedicine. Today, digitization is the theme driving many
of these companies: "In the future, big data will be essential to
the life sciences. The challenge will be to derive new knowledge
from this multiplicity of complex data, for example in cancer
research and in the field of personalized medicine," notes Dr. Kai
Uwe Bindseil, manager of the HealthCapital cluster. Here, the
emphasis is placed on first-class R&D facilities such the Berlin
Institute of Health (BIH), which focuses on translational research
and precision medicine.
BIO-Europe will no doubt generate considerable attention for
Berlin among the global community of experts before, during and
after the conference. International guests will be given a great
opportunity to personally acquaint themselves with the capital as a
leading location for the biotech and pharma industry. This is
indeed the unique advantage of international meetings that take
place at a different location each year. As cluster manager Dr.
Bindseil argues, visitors to Berlin are consistently most
fascinated by the impressive industry numbers, the verve of the
city and its unique entrepreneurial spirit: "The large pool of
international talent and the dynamic founders' scene continue to
inspire companies from all over the world to come to Berlin and
launch development centers here. Large pharmaceutical companies
like Bayer and Pfizer seek out contact to startups and work with
them on innovations and new business models in labs, incubators and
special startup programs."
Contact:
Lukas Breitenbach
Spokesman
Tel +49 30 46302-599
Lukas.Breitenbach@berlin-partner.de
Berlin Partner für Wirtschaft und Technologie GmbH
www.berlin-partner.de/en
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.